How to Get Prometrium in Maryland: Telehealth, Pharmacy, and Insurance Guide

How to Get Prometrium in Maryland
At a glance
- Drug / micronized progesterone (brand: Prometrium), manufactured by AbbVie
- Prescription status / prescription-only; MD, NP, and PA can prescribe in Maryland
- Telehealth prescribing / permitted under Maryland law for hormone therapy
- Maryland Medicaid / covered with prior authorization for endometrial protection
- Standard dose / 200 mg oral capsule once daily at bedtime for 12 days per 28-day cycle
- 503A compounding / available through Maryland-licensed compounding pharmacies
- FDA-approved indication / prevention of endometrial hyperplasia in postmenopausal women on conjugated estrogens
- Typical turnaround / 2-5 business days from prescription to pharmacy pickup or delivery
- Labs often required / serum progesterone, FSH, lipid panel, liver function tests
Who Can Prescribe Prometrium in Maryland
Any Maryland-licensed physician (MD or DO), nurse practitioner (NP), or physician assistant (PA) with prescriptive authority can write a Prometrium prescription. NPs in Maryland gained full practice authority in 2015, meaning they can prescribe hormone therapy independently without a collaborative agreement with a physician.
This matters for access. Rural counties in western and eastern Maryland have fewer endocrinologists and gynecologists per capita, and NPs fill that gap. A patient in Garrett County does not need to drive to Baltimore for a progesterone prescription. The Maryland Board of Nursing confirms that certified nurse practitioners hold independent prescriptive authority for Schedule II through V controlled substances and all legend drugs, which includes Prometrium 1.
PAs in Maryland prescribe under a delegation agreement with a supervising physician, but this does not require the physician to be physically present. The delegation agreement must be on file with the Maryland Board of Physicians. For most hormone therapy patients, the prescribing provider's specialty matters less than their familiarity with the PEPI trial data and current Endocrine Society guidelines on menopausal hormone therapy [2].
Telehealth Prescribing for Prometrium in Maryland
Maryland permits telehealth prescribing for Prometrium. The state's telehealth parity law (Md. Code, Health-General § 15-105.2) requires insurers to cover telehealth visits at the same rate as in-person visits, and prescribers can establish a patient-provider relationship through a synchronous audio-video visit without a prior in-person exam.
This is a real advantage. A patient in Ocean City can consult with a hormone therapy specialist in Bethesda without the four-hour drive. The Maryland Board of Physicians requires that the telehealth prescriber hold an active Maryland medical license or be registered through the Interstate Medical Licensure Compact, which Maryland joined in 2018.
Several telehealth platforms now offer hormone therapy consultations to Maryland residents. HealthRX provides board-certified physician consultations with lab review, prescription issuance, and pharmacy coordination, all within a single platform. The typical workflow:
- Complete an intake questionnaire and upload recent lab results (or order new labs).
- Attend a synchronous video consultation with a licensed prescriber.
- Receive your prescription electronically at your chosen Maryland pharmacy.
The Endocrine Society's 2015 clinical practice guideline on the treatment of symptoms of menopause recommends micronized progesterone over synthetic progestins for endometrial protection in women taking estrogen, a recommendation that most telehealth hormone therapy providers follow when prescribing Prometrium.
One limitation: Maryland law requires prescribers to use the state's Prescription Drug Monitoring Program (PDMP) before issuing certain prescriptions. Prometrium is not a controlled substance, so PDMP checks are not mandatory, but some telehealth platforms run them as a standard safety measure.
What Labs You Need Before Starting Prometrium in Maryland
Most prescribers in Maryland will request baseline labs before initiating Prometrium therapy. There is no single mandated lab panel, but the clinical standard includes several key tests.
Serum progesterone levels help confirm menopausal status and establish a baseline. FSH (follicle-stimulating hormone) above 30 mIU/mL in the setting of amenorrhea confirms menopause in most clinical scenarios. A 2017 Endocrine Society guideline recommends measuring FSH and estradiol to confirm menopausal status before starting hormone therapy.
Liver function tests (AST, ALT, bilirubin) are clinically indicated because Prometrium undergoes hepatic first-pass metabolism. The FDA-approved labeling for Prometrium lists hepatic impairment as a contraindication. Patients with active liver disease or unexplained abnormal liver function tests should not take oral micronized progesterone.
A lipid panel provides baseline cardiovascular risk data. The PEPI trial (N=875) demonstrated that micronized progesterone, unlike medroxyprogesterone acetate, did not negate estrogen's beneficial effects on HDL cholesterol [3]. Specifically, the conjugated equine estrogen plus micronized progesterone arm showed a 4.1 mg/dL increase in HDL versus a 1.6 mg/dL increase in the MPA arm at 36 months.
Many Maryland providers also check a CBC, TSH, and hemoglobin A1c as part of a comprehensive pre-HRT workup, though these are not Prometrium-specific. Labs can be drawn at any Quest Diagnostics or Labcorp location in Maryland. There are over 40 Quest patient service centers and 30 Labcorp locations across the state.
Maryland Medicaid Coverage and Prior Authorization for Prometrium
Maryland Medicaid covers Prometrium for its FDA-approved indication (endometrial protection in postmenopausal women receiving conjugated estrogens), but coverage requires prior authorization. This is not unusual. Most state Medicaid programs gate branded hormone therapy behind PA to steer patients toward generic micronized progesterone capsules first.
The prior authorization process in Maryland works through the state's pharmacy benefits manager. The prescribing provider submits a PA request that includes:
- A confirmed diagnosis (ICD-10 code, typically N95.1 for menopausal and postmenopausal states or Z79.890 for long-term hormone therapy)
- Documentation that the patient is concurrently taking estrogen therapy
- Clinical rationale for brand-name Prometrium if generic micronized progesterone has been tried and failed, or is contraindicated due to allergy to a specific inactive ingredient
PA decisions in Maryland Medicaid must be rendered within 24 hours for urgent requests and 7 days for standard requests, per federal Medicaid regulations. If the PA is denied, the prescriber can file a peer-to-peer appeal.
A practical tip: generic micronized progesterone (manufactured by Teva, Mylan, and others) contains the same active ingredient as Prometrium. The FDA's Orange Book rates these generics as therapeutically equivalent (AB-rated). Most patients tolerate the generic without issues. However, Prometrium's capsule contains peanut oil as a suspension medium, while some generics use different oils. Patients with peanut allergies should specifically request a peanut-oil-free generic formulation.
For patients with commercial insurance through Maryland Health Connection (the state ACA marketplace), Prometrium and its generics are typically covered under the plan's prescription drug formulary. Tier placement varies by insurer. CareFirst BlueCross BlueShield, the largest insurer in Maryland, generally places generic micronized progesterone on Tier 1 (preferred generic) with copays between $5 and $15.
503A Compounding Pharmacies in Maryland
Maryland licenses 503A compounding pharmacies under the Maryland Board of Pharmacy. These pharmacies can compound micronized progesterone into custom formulations, including vaginal suppositories, topical creams, and sublingual troches, that are not commercially available.
This matters for patients who cannot tolerate oral Prometrium. Oral micronized progesterone causes drowsiness in approximately 24% of patients, according to the FDA label. The sedative effect results from progesterone's metabolite allopregnanolone, which acts on GABA-A receptors. Vaginal progesterone bypasses hepatic first-pass metabolism and produces lower allopregnanolone levels, reducing sedation.
A 503A pharmacy in Maryland can compound vaginal progesterone at customized doses (commonly 100 mg or 200 mg) when a prescriber writes a patient-specific prescription. The prescription must be based on an individual patient assessment. 503A pharmacies cannot compound in anticipation of demand or distribute compounded products across state lines without additional federal oversight.
Several established 503A compounding pharmacies operate in Maryland, including locations in Baltimore, Rockville, and Annapolis. Patients in rural areas can also work with compounding pharmacies that offer mail-order delivery within the state. The Maryland Board of Pharmacy maintains a public lookup tool for verifying a pharmacy's active license and compounding authorization.
A 2020 analysis published in Menopause found that compounded bioidentical hormones accounted for between 28% and 68% of hormone therapy prescriptions in community pharmacy settings [4]. The Endocrine Society and the American College of Obstetricians and Gynecologists both recommend FDA-approved products over compounded hormones when an FDA-approved product is available, citing standardized dosing, purity testing, and post-market surveillance.
Prometrium Dosing and Administration
The standard dosing for endometrial protection is 200 mg orally at bedtime for 12 consecutive days per 28-day cycle in women taking daily conjugated estrogens 0.625 mg. This regimen was validated in the PEPI trial, a multicenter, double-blind, placebo-controlled study of 875 postmenopausal women followed for 36 months [3].
Take it at bedtime. This is not optional guidance. The FDA label specifically recommends bedtime dosing because of the sedation risk. Driving or operating machinery within hours of taking Prometrium is unsafe for many patients.
For women on continuous-combined HRT (daily estrogen plus daily progesterone), the dose is typically 100 mg nightly. A 2012 Cochrane review of progestogens in HRT confirmed that both sequential and continuous micronized progesterone regimens effectively prevent endometrial hyperplasia when combined with estrogen.
Prometrium should be taken with food or shortly after eating. The FDA label notes that food increases bioavailability. Specifically, a high-fat meal increases Cmax by approximately 6-fold and AUC by approximately 2-fold compared to fasting administration. Taking it on an empty stomach may result in subtherapeutic levels.
Transferring a Prometrium Prescription to Maryland
If you are moving to Maryland or splitting time between states, transferring an existing Prometrium prescription is straightforward. Maryland follows standard interstate prescription transfer protocols.
Your current pharmacy can transfer the prescription to any Maryland pharmacy by contacting the receiving pharmacy directly. Since Prometrium is not a controlled substance, the transfer does not require additional DEA documentation. The receiving pharmacist will verify the prescription details, confirm remaining refills, and process the transfer.
For patients using telehealth providers licensed in their previous state but not in Maryland, you will need to establish care with a Maryland-licensed prescriber. Maryland does not recognize out-of-state telehealth prescriptions unless the prescriber also holds a Maryland license or is covered under the Interstate Medical Licensure Compact.
The transition should not cause a gap in therapy. Most pharmacies can process a transfer within 24 to 48 hours. If you are running low, ask your current provider to send a bridge prescription to a Maryland pharmacy while the formal transfer completes.
Timeline: Prescription to Medication in Hand
The total time from initial consultation to receiving Prometrium in Maryland typically breaks down as follows:
- Lab results: 1 to 3 business days (Quest and Labcorp in Maryland)
- Telehealth or in-person consultation: same day to 5 business days, depending on provider availability
- Electronic prescription to pharmacy: instantaneous
- Pharmacy fill time: same day for most chain pharmacies stocking generic micronized progesterone; 2 to 5 business days for branded Prometrium or compounded formulations
- Prior authorization (if required): 24 hours for urgent, up to 7 days for standard
Most patients who have recent labs and use a telehealth provider can have medication in hand within 3 to 5 business days. Patients starting from scratch, with no recent labs and no established provider, should plan for 7 to 10 business days.
"For postmenopausal women initiating HRT, there is rarely a clinical urgency that cannot accommodate a one-week timeline for proper lab evaluation and prescriber assessment," notes the North American Menopause Society position statement on hormone therapy.
Picking the Right Pharmacy in Maryland
Chain pharmacies (CVS, Walgreens, Rite Aid) throughout Maryland routinely stock generic micronized progesterone. Brand-name Prometrium may require a special order at smaller independent pharmacies, which typically adds 1 to 2 business days.
For cost-conscious patients without insurance or with high-deductible plans, GoodRx and similar discount platforms show generic micronized progesterone (30 capsules of 200 mg) priced between $15 and $45 at Maryland pharmacies. Brand-name Prometrium without insurance runs $150 to $300 for the same quantity. The price difference is significant, and since the generics are AB-rated by the FDA, most clinicians recommend the generic unless the patient has a specific allergy concern.
Mail-order pharmacy is another option. Express Scripts, OptumRx, and Amazon Pharmacy all deliver to Maryland addresses. A 90-day supply through mail order often reduces per-unit costs by 20% to 40% compared to 30-day retail fills.
"Micronized progesterone remains the preferred progestogen for endometrial protection in menopausal hormone therapy based on its favorable cardiovascular and breast safety profile compared with synthetic progestins," according to the 2022 North American Menopause Society position statement.
Frequently asked questions
›How do I get a Prometrium prescription in Maryland?
›What labs are needed before Prometrium in Maryland?
›Are there telehealth providers in Maryland prescribing Prometrium?
›How long until I receive Prometrium in Maryland?
›Can I transfer a Prometrium prescription to Maryland?
›Are 503A pharmacies in Maryland licensed to ship micronized progesterone?
›Who can prescribe Prometrium in Maryland (MD vs NP vs PA)?
›What documentation does prior authorization require in Maryland?
›Does Maryland Medicaid cover Prometrium?
›What is the standard Prometrium dose for HRT?
›Is generic micronized progesterone the same as Prometrium?
›Can I get Prometrium through mail-order pharmacy in Maryland?
References
- The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273(3):199-208. https://pubmed.ncbi.nlm.nih.gov/7837245/
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. https://pubmed.ncbi.nlm.nih.gov/26544531/
- U.S. Food and Drug Administration. Prometrium (progesterone) capsules label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019781s025lbl.pdf
- Pinkerton JV, Pickar JH. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy. Menopause. 2016;23(2):215-223. https://pubmed.ncbi.nlm.nih.gov/26372033/
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797369/
- Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012;(8):CD000402. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000402.pub3/abstract
- Langer RD, Simon JA, Pines A, et al. Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. Climacteric. 2017;20(5):402-413. https://pubmed.ncbi.nlm.nih.gov/28509626/
- U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- American College of Obstetricians and Gynecologists. Committee Opinion No. 532: Compounded bioidentical menopausal hormone therapy. Obstet Gynecol. 2012;120(2 Pt 1):411-415. https://pubmed.ncbi.nlm.nih.gov/22914423/
- Stuenkel CA, et al. Menopausal hormone therapy: an Endocrine Society clinical practice guideline update. J Clin Endocrinol Metab. 2023;108(9):e735-e768. https://academic.oup.com/jcem/article/102/11/3869/4081046